Privileged Structures in Drug Discovery : (Record no. 188)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11153nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC5317897 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724113051.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2018 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118686331 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781118145661 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC5317897 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL5317897 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11523890 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1028552135 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RS403 .Y48 2018 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.1/9 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Yet, Larry. |
| 245 10 - TITLE STATEMENT | |
| Title | Privileged Structures in Drug Discovery : |
| Remainder of title | Medicinal Chemistry and Synthesis. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2018. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2018. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (561 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Title Page -- Copyright Page -- Contents -- Chapter 1 Introduction -- 1.1 The Original Definition of Privileged Structures -- 1.2 The Role of Privileged Structures in the Drug Discovery Process -- 1.3 The Loose Definitions of "Privileged Structures" -- 1.4 Synthesis and Biological Activities of Carbocyclic and Heterocyclic Privileged Structures -- 1.4.1 Synthesis and Biological Activities of Three- and Four-Membered Ring Privileged Structures -- 1.4.2 Synthesis and Biological Activities of Five-Membered Ring Privileged Structures -- 1.4.3 Synthesis and Biological Activities of Six-Membered Ring Privileged Structures -- 1.4.4 Synthesis and Biological Activities of Bicyclic 5/5 and 6/5 Ring Privileged Structures -- 1.4.5 Synthesis and Biological Activities of Bicyclic 6/6 and 6/7 Ring Privileged Structures -- 1.4.6 Synthesis and Biological Activities of Tricyclic and Tetracyclic Ring Privileged Structures -- 1.5 Combinatorial Libraries of "Privileged Structures" -- 1.6 Scope of this Monograph -- References -- Chapter 2 Benzodiazepines -- 2.1 Introduction -- 2.2 Marketed BDZ Drugs -- 2.2.1 1,4-Benzodiazepine Marketed Drugs -- 2.2.2 1,5-Benzodiazepine Marketed Drugs -- 2.2.3 Linearly Fused BDZ Marketed Drugs -- 2.2.4 Angularly Fused-1,4-Benzodiazepine Marketed Drugs -- 2.3 Medicinal Chemistry Case Studies -- 2.3.1 Cardiovascular Applications -- 2.3.2 Central Nervous System Applications -- 2.3.3 Gastrointestinal Applications -- 2.3.4 Infectious Diseases Applications -- 2.3.5 Inflammation Applications -- 2.3.6 Metabolic Diseases Applications -- 2.3.7 Oncology Applications -- 2.4 Synthesis of BDZs -- 2.4.1 Condensation of o-Phenylenediamines to 1,5-Benzodiazepines -- 2.4.1.1 Condensation of o-Phenylenediamines with Ketones -- 2.4.1.2 Condensation of o-Phenylenediamines with α,β-Unsaturated Ketones. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 2.4.1.3 Condensation of o-Phenylenediamines with Alkynes -- 2.4.2 Reductive Condensation of α-Substituted Nitrobenzenes with Ketones and α,β-Unsaturated Ketones -- 2.4.3 Intramolecular Cyclizations to 1,4-Benzodiazepines -- 2.4.3.1 Intramolecular Cyclizations-Path A -- 2.4.3.2 Intramolecular Cyclizations-Path B -- 2.4.3.3 Intramolecular Cyclizations-Path C -- 2.4.3.4 Intramolecular Cyclizations-Path D -- 2.4.3.5 Intramolecular Cyclizations-Path E -- 2.4.3.6 Intramolecular Cyclizations-Path F -- 2.4.3.7 Intramolecular Cyclizations-Path G -- 2.4.3.8 Intramolecular Cyclizations-Path H -- 2.4.4 Ugi Multicomponent Synthesis -- 2.4.5 Elaboration of 1,4-Benzodiazepines -- 2.4.6 Pyrrolo[2,1-c]benzodiazepines -- 2.4.7 Fused BDZ Ring Systems -- 2.4.8 Solid-Phase Synthesis of BDZs -- References -- Chapter 3 1,4-Dihydropyridines -- 3.1 Introduction -- 3.2 Marketed 1,4-Dihyropyridine Drugs -- 3.3 Medicinal Chemistry Case Studies -- 3.3.1 Cardiovascular Applications -- 3.3.2 Central Nervous System Applications -- 3.3.3 Infectious Diseases Applications -- 3.3.4 Inflammation Applications -- 3.3.5 Men's and Women's Health Issues Applications -- 3.3.6 Metabolic Diseases Applications -- 3.3.7 Oncology Applications -- 3.4 Synthesis of 1,4-Dihydropyridines -- 3.4.1 Classical Hantzsch Synthesis -- 3.4.2 Modified Hantzsch Conditions -- 3.4.3 1,4-Disubstituted-1,4-Dihydropyridines -- 3.4.4 Organometallic Additions to Pyridinium Salts -- 3.4.5 From Imines and Enamino Compounds -- 3.4.6 Multicomponent Synthesis -- 3.4.6.1 Three-Component Synthesis of 1,4-Dihydropyridines -- 3.4.6.2 Four-Component Synthesis of 1,4-Dihydropyridines -- 3.4.7 Organocatalytic Synthesis of 1,4-Dihydropyridines -- 3.4.8 Miscellaneous Preparations -- 3.4.9 Elaboration of 1,4-Dihydropyridines -- References -- Chapter 4 Biaryls -- 4.1 Introduction -- 4.2 Marketed Biaryl Drugs. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 4.3 Medicinal Chemistry Case Studies -- 4.3.1 Cardiovascular Applications -- 4.3.2 Central Nervous System Applications -- 4.3.3 Infectious Diseases Applications -- 4.3.4 Inflammation Applications -- 4.3.5 Men's and Women's Health Issues Applications -- 4.3.6 Metabolic Diseases Applications -- 4.3.7 Oncology Applications -- 4.4 Synthesis of Biaryls -- 4.4.1 Transition Metal-Catalyzed Cross-Coupling Synthesis -- 4.4.1.1 Suzuki-Miyaura Cross-Coupling Reactions with Boronic Acids -- 4.4.1.2 Suzuki-Miyaura Cross-Coupling Reactions with Boronate Esters -- 4.4.1.3 Metal-Catalyzed Homocoupling Reactions -- 4.4.1.4 Uhlmann Coupling Reactions -- 4.4.1.5 Kumada-Tamao-Corriu Cross-Coupling Reactions -- 4.4.1.6 Negishi Cross-Coupling Reactions -- 4.4.1.7 Hiyama Cross-Coupling Reactions -- 4.4.1.8 Stille Cross-Coupling Reactions -- 4.4.1.9 Miscellaneous Cross-Coupling Reactions -- 4.4.1.10 Metal-Catalyzed Functional Group Removal Cross-Coupling Reaction -- 4.4.2 C─H Functionalization Reactions -- 4.4.2.1 Oxidative Coupling Reactions -- 4.4.2.2 Direct C─H Arylations -- 4.4.2.3 C─H Functionalization with Directing Groups -- 4.4.3 Cycloaddition Reactions -- 4.4.3.1 [3+3] Cycloaddition Reactions -- 4.4.3.2 [4+2] Cycloaddition Reactions -- 4.4.3.3 [2+2+2] Cycloaddition Reactions -- 4.4.3.4 Tandem Cycloaddition Reactions -- 4.4.4 Biaryl Phenol Syntheses -- 4.4.5 Miscellaneous Syntheses -- References -- Chapter 5 4-(Hetero)Arylpiperidines -- 5.1 Introduction -- 5.2 Marketed 4-(Hetero)Arylpiperidine Drugs -- 5.3 Medicinal Chemistry Case Studies -- 5.3.1 Cardiovascular Applications -- 5.3.2 Central Nervous System Applications -- 5.3.3 Infectious Diseases Applications -- 5.3.4 Inflammation Applications -- 5.3.5 Men's and Women's Health Applications -- 5.3.6 Metabolic Diseases Applications -- 5.3.7 Oncology Applications -- 5.4 Synthesis of 4-(Hetero)Arylpiperidines. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 5.4.1 Preparation from 4-Piperidinones -- 5.4.2 Preparation from 4-Prefunctionalized- 3-alkenylpiperidines -- 5.4.3 Preparation from Negishi Cross-Coupling of 3-Zincated Piperidines -- 5.4.4 Preparation from 4-Funtionalized Piperidines -- 5.4.5 Conjugated Addition to Unsaturated Piperidines -- 5.4.6 Miscellaneous Syntheses -- References -- Chapter 6 Spiropiperidines -- 6.1 Introduction -- 6.2 Marketed Spiropiperidine Drugs -- 6.3 Medicinal Chemistry Case Studies -- 6.3.1 Cardiovascular Applications -- 6.3.2 Central Nervous System Applications -- 6.3.3 Infectious Diseases Applications -- 6.3.4 Inflammation Applications -- 6.3.5 Men's and Women's Health Applications -- 6.3.6 Metabolic Diseases Applications -- 6.3.7 Oncology Applications -- 6.4 Synthesis of Spiropiperidines -- 6.4.1 Quinolinylspiropiperidines -- 6.4.2 Azaspiro[5.5]alkane Systems -- 6.4.3 Diazaspiro[5.5]alkane Derivatives -- 6.4.4 1,4-Benzodioxinylspiropiperidines -- 6.4.5 Spirobenzooxazinylspiropiperidines -- 6.4.6 (Iso)Quinolinylspiropiperidines -- 6.4.7 Indenospiropiperidines -- 6.4.8 Indolin(on)ylspiropiperidines -- 6.4.9 Cyclohexadienonylspiropiperidines -- 6.4.10 Cyclopenta[b]pyrrolospiropiperidines -- 6.4.11 Chromanylspiropiperidines -- 6.4.12 (Iso)Benzofuran(on)ylspiropiperidines -- 6.4.13 Indenospiropiperidines -- References -- Chapter 7 2-Aminopyrimidines -- 7.1 Introduction -- 7.2 Marketed 2-Aminopyrimidine Drugs -- 7.3 Medicinal Chemistry Case Studies -- 7.3.1 Cardiovascular Applications -- 7.3.2 Central Nervous System Applications -- 7.3.3 Infectious Diseases Applications -- 7.3.4 Inflammation Applications -- 7.3.5 Metabolic Diseases Applications -- 7.3.6 Miscellaneous Applications -- 7.3.7 Oncology Applications -- 7.4 Synthesis of 2-Aminopyrimidines -- 7.4.1 Aminations with 2-Halo or 2,4-Dihalopyrimidines -- 7.4.2 Cross-Coupling Reactions with 2-Aminopyrimidines. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 7.4.3 Aminations with 2-Sulfonylpyrimidines -- 7.4.4 Cyclizations with Guanidines -- References -- Chapter 8 2-Aminothiazoles -- 8.1 Introduction -- 8.2 Marketed 2-Aminothiazole Drugs -- 8.3 Medicinal Chemistry Case Studies -- 8.3.1 Cardiovascular Diseases Applications -- 8.3.2 Central Nervous System Applications -- 8.3.3 Infectious Diseases Applications -- 8.3.4 Inflammation Applications -- 8.3.5 Metabolic Diseases Applications -- 8.3.6 Oncology Applications -- 8.3.7 Miscellaneous Applications -- 8.4 Synthesis of 2-Aminothiazoles -- 8.4.1 Hantzsch Synthesis from α-Functionalized Ketones and Thioureas -- 8.4.2 Hantzsch Synthesis from Ketones and Thioureas -- 8.4.3 Synthesis from α-Haloketones and Thiocyanates -- 8.4.4 Synthesis from Vinyl Azides and Thiocyanates -- 8.4.5 Synthesis from Amidines and Thiocyanates -- 8.4.6 Synthesis from Alkenyl and Alkynyl Compounds with Thiocyanates or Thioureas -- 8.4.7 Miscellaneous Syntheses -- 8.4.8 Elaboration of 2-Aminothiazoles -- References -- Chapter 9 2-(Hetero)Arylindoles -- 9.1 Introduction -- 9.2 Marketed 2-Arylindole Drugs -- 9.3 Medicinal Chemistry Case Studies -- 9.3.1 Cardiovascular Applications -- 9.3.2 Central Nervous System Applications -- 9.3.3 Infectious Diseases Applications -- 9.3.4 Inflammation Applications -- 9.3.5 Men's and Women's Health Applications -- 9.3.6 Metabolic Diseases Applications -- 9.3.7 Miscellaneous Applications -- 9.3.8 Oncology Applications -- 9.4 Synthesis of 2‐(Hetero)Arylindoles -- 9.4.1 Functionalization to the Preformed Indole System -- 9.4.1.1 2-Functionalized Metallated Indoles with Aryl Halides (Strategy 1) -- 9.4.1.2 2-Halogenated or 2-Triflated Indoles with Functionalized Arenes (Strategy 1) -- 9.4.1.3 Direct Arylation of Indole with Functionalized Arenes (Strategy 2) -- 9.4.1.4 Direct Oxidative Coupling of Indoles with (Hetero)Arenes (Strategy 3). |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 9.4.2 Fischer Indole Synthesis. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutical chemistry. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug development-Methodology. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Yet, Larry |
| Title | Privileged Structures in Drug Discovery |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2018 |
| International Standard Book Number | 9781118145661 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5317897">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5317897</a> |
| Public note | Click to View |
No items available.